Moleculin Biotech (MBRX) Share-based Compensation (2016 - 2026)
Moleculin Biotech (MBRX) posted quarterly Share-based Compensation of $459000.0 for Q4 2025, down 73.0% year-over-year from $1.7 million in Q4 2024, and up 51.49% quarter-over-quarter from $303000.0 in Q3 2025.
Moleculin Biotech (MBRX) Share-based Compensation (2016 - 2026) Analysis & Trends
Moleculin Biotech's Share-based Compensation history runs 10 years deep, the most recent figure standing at $459000.0 for Q4 2025.
- In Q4 2025, Share-based Compensation fell 73.0% year-over-year to $459000.0; the TTM figure through Dec 2025 stood at $1.7 million (down 44.51% YoY), while the FY2025 annual figure was $1.7 million, down 3.59% from the prior year.
- Share-based Compensation for Q4 2025 stood at $459000.0, up from $303000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $2.3 million in Q4 2021, with the low at $303000.0 in Q3 2025.
- The 5-year median for Share-based Compensation is $496000.0 (2023), against an average of $728300.0.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation tumbled 77.22% in 2022, then surged 266.17% in 2023.
- Moleculin Biotech's Share-based Compensation stood at $2.3 million in 2021, then sank by 77.22% to $535000.0 in 2022, then soared by 266.17% to $2.0 million in 2023, then retreated by 13.22% to $1.7 million in 2024, then sank by 73.0% to $459000.0 in 2025.
- Business Quant data shows MBRX's Share-based Compensation at $459000.0 in Q4 2025, $303000.0 in Q3 2025, and $417000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | - |
| 10 | Moleculin Biotech | 3.30 Mn | 3.30 Mn | - | 436,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 436,000.00 |
| Jun 30, 2026 | 436,000.00 |
| Dec 31, 2025 | 459,000.00 |
| Dec 31, 2025 | 459,000.00 |
| Sep 30, 2025 | 303,000.00 |
| Sep 30, 2025 | 303,000.00 |
| Jun 30, 2025 | 417,000.00 |
| Jun 30, 2025 | 417,000.00 |
| Mar 31, 2025 | 485,000.00 |
| Mar 31, 2025 | 485,000.00 |
| Dec 31, 2024 | 1.70 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Sep 30, 2024 | 353,000.00 |
| Sep 30, 2024 | 353,000.00 |
| Jun 30, 2024 | 453,000.00 |
| Jun 30, 2024 | 453,000.00 |
| Mar 31, 2024 | 493,000.00 |
| Mar 31, 2024 | 493,000.00 |
| Dec 31, 2023 | 1.96 Mn |
| Dec 31, 2023 | 1.96 Mn |